(Q44051897)

29 November 2017

title

The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients (English)

1 reference

29 November 2017

0 references

0 references

2

Paola Baiardi

1 reference

29 November 2017

Adriana Ceci

1

1 reference

29 November 2017

Mariagrazia Felisi

3

1 reference

29 November 2017

Maria Domenica Cappellini

4

1 reference

29 November 2017

Vittorio Carnelli

5

1 reference

29 November 2017

Vincenzo De Sanctis

6

1 reference

29 November 2017

Renzo Galanello

7

1 reference

29 November 2017

Aurelio Maggio

8

1 reference

29 November 2017

Giuseppe Masera

9

1 reference

29 November 2017

Antonio Piga

10

1 reference

29 November 2017

Francesco Schettini

11

1 reference

29 November 2017

Ippazio Stefàno

12

1 reference

29 November 2017

Fernando Tricta

13

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

British Journal of Haematology

29 November 2017

published in

1 reference

29 November 2017

volume

118

1 reference

29 November 2017

issue

1

1 reference

29 November 2017

page(s)

330-336

1 reference

Meta-analytic review of the clinical effectiveness of oral deferiprone (L1).

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03554.X

Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03554.X

Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03554.X

The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03554.X

Good practice in the postmarketing surveillance of medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03554.X

Long-term therapy with deferiprone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03554.X

Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03554.X

A risk-benefit assessment of iron-chelation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03554.X

Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03554.X

Arthropathy in thalassaemia patients receiving deferiprone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03554.X

10.1046/J.1365-2141.2002.03554.X

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference